Eyenovia Management

Management criteria checks 1/4

Eyenovia's CEO is Michael Rowe, appointed in Jul 2018, has a tenure of 5.75 years. total yearly compensation is $1.33M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.065% of the company’s shares, worth $17.45K. The average tenure of the management team and the board of directors is 5.8 years and 2.2 years respectively.

Key information

Michael Rowe

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage38.4%
CEO tenure5.8yrs
CEO ownership0.06%
Management average tenure5.8yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Jan 30
Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Oct 14
Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Jun 27
Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Oct 25
Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Oct 05

Eyenovia names Michael Rowe as new CEO

Jul 27

New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)

Apr 03
New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)

Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 31
Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Eyenovia: I Can See You Better - Now

Mar 04

Eyenovia: Reassessing After The FDA Moves The Goalposts

Nov 23

Eyenovia: FDA Setback Is Big Opportunity For Investors

Nov 08

Eyenovia: Can You See Me Now?

Oct 21

Is Eyenovia (NASDAQ:EYEN) A Risky Investment?

Sep 16
Is Eyenovia (NASDAQ:EYEN) A Risky Investment?

Eyenovia updates on late-stage program for presbyopia therapy

Jun 15

Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation

Jun 02

Eyenovia announces new $25M credit facility with Silicon Valley Bank

May 10

Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN)

Mar 09
Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN)

CEO Compensation Analysis

How has Michael Rowe's remuneration changed compared to Eyenovia's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$27m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$1mUS$512k

-US$28m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$1mUS$360k

-US$13m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$665kUS$275k

-US$20m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$482kUS$275k

-US$21m

Compensation vs Market: Michael's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD673.36K).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.


CEO

Michael Rowe (61 yo)

5.8yrs

Tenure

US$1,333,510

Compensation

Mr. Michael M. Rowe serves as Chief Executive Officer at Eyenovia, Inc. since August 01, 2022 and is its Director since August 2022. He had been Chief Operating Officer of Eyenovia, Inc. since January 31,...


Leadership Team

NamePositionTenureCompensationOwnership
Tsontcho Ianchulev
Co-Founder & Executive Chairman10.1yrsUS$1.03m0.66%
$ 178.7k
Michael Rowe
CEO & Director5.8yrsUS$1.33m0.065%
$ 17.5k
John Gandolfo
CFO & Secretary6.3yrsUS$651.29k0.016%
$ 4.2k
Bren Kern
COO & Corporate VP1.3yrsno data0.0049%
$ 1.3k
Alexander Lobo
Investor Contactno datano datano data

5.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: EYEN's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tsontcho Ianchulev
Co-Founder & Executive Chairman10.1yrsUS$1.03m0.66%
$ 178.7k
Michael Rowe
CEO & Director1.7yrsUS$1.33m0.065%
$ 17.5k
Charles Mather
Independent Director6.1yrsUS$148.70k0.15%
$ 41.1k
Michael Geltzeiler
Independent Directorless than a yearno datano data
Robert Weinreb
Member of Scientific Advisory Boardno datano datano data
Ellen Strahlman
Independent Director1.8yrsUS$109.30k0.11%
$ 30.7k
James Tsai
Member of Scientific Advisory Boardno datano datano data
Ram Palanki
Independent Director1.8yrsUS$100.55k0.040%
$ 10.7k
Pamela Gallin
Member of Scientific Advisory Boardno datano datano data
Mark Bullimore
Member of Scientific Advisory Board4.3yrsno datano data
April Jasper
Member of Scientific Advisory Board4.3yrsno datano data
Rachel Jacobson
Independent Director2.2yrsUS$138.39k0.050%
$ 13.5k

2.2yrs

Average Tenure

61yo

Average Age

Experienced Board: EYEN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.